All HHS Contracts — August 09, 2026

SIGA's firm-fixed-price contract for smallpox antiviral drug development and procurement provides $447.2M already outlayed and revenue visibility through 2029, signaling strong government commitment to biodefense preparedness.

The time-and-materials structure and 6-month base period create high pricing risk and dependency on option exercises, while the nonprofit status raises questions about financial capacity to execute a contract of this scale.

SIGA TECHNOLOGIES faces medium execution risk on its $626.5M firm-fixed-price contract; if development costs exceed estimates, margins could compress despite the fixed-price structure.

OUR RESCUE's $158.1M contract has a 6-month base period ending February 2027; failure to exercise options could result in abrupt revenue loss and questions about HHS legal services continuity.

SIGA TECHNOLOGIES derives 80% of this digest's total obligation from a single contract, indicating high revenue concentration risk for the company.

SIGA TECHNOLOGIES' $626.5M contract with BARDA underscores growing biodefense spending; follow-on contracts or option exercises could increase total value and signal sector growth.

OUR RESCUE's non-competed $158.1M award suggests specialized legal capability; if options are exercised, it could lead to a sole-source bridge to a larger competitive procurement, benefiting the incumbent.

SIGA TECHNOLOGIES' $626.5M contract for smallpox antiviral development and procurement demonstrates sustained HHS/BARDA investment in biodefense, with long-term revenue visibility through 2029.

OUR RESCUE's $158.1M non-competed time-and-materials contract for legal support services indicates HHS reliance on sole-source awards to maintain operational continuity, but carries high pricing risk.

{"entity" => "SIGA TECHNOLOGIES", "reason" => "Holds $626.5M BARDA contract with $447.2M already outlayed; revenue visibility through 2029 but fixed-price execution risk.", "trigger" => "Quarterly earnings reports, contract modifications, new BARDA antiviral solicitations"}

{"entity" => "OUR RESCUE", "reason" => "Non-competed $158.1M HHS legal services contract with 6-month base period; option exercise critical for revenue continuity.", "trigger" => "Option exercise decision before February 2027, competitive re-solicitation announcements"}

{"entity" => "HHS/BARDA", "reason" => "Dominant agency in this digest; future biodefense procurement signals will impact SIGA and sector peers.", "trigger" => "NDAA biodefense funding provisions, new BARDA solicitations for antiviral development"}